An exploratory study on the efficacy and safety of Hangesyasinto (TJ-14) for DCF chemotherapy or DCF-RT chemoradiotherapy induced diarrhea in the patients with advanced esophageal cancer.
Not Applicable
Recruiting
- Conditions
- esophageal cancer
- Registration Number
- JPRN-UMIN000023825
- Lead Sponsor
- Dokkyo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
1. aldosteronism 2. myopathy or hypokalemia 3. while taking the Kampo medicines 4. less than 4 weeks after previous chemo or radio completion 5. medical history of serious drug allergy 6. presence of serious complications (heart, lung, liver, or kidney disease or psychological disorders or bleeding) 7. HBV, HCV infection 8. pregnant or breast-feeding females and females who have a possibility of pregnancy 9. patients who are thought inadequate by their doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method